Search results
Showing 106 to 120 of 729 results for diabet*
Aflibercept for untreated diabetic macular oedema [TSID10621]
Topic prioritisation
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
This indicator covers the percentage of patients with hypertension or diabetes and a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been referred to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM203
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)
Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
UrgoStart for treating diabetic foot ulcers and leg ulcers (HTG502)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.